<h2 id="what-is-succinylcholine-">What is Succinylcholine? <sup id="fnref:1" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup></h2>
<ul>
  <li>A depolarizing neuromuscular blocking drug</li>
  <li>Commonly used for rapid sequence induction and intubation due to its rapid onset and ultra-short duration of action.</li>
</ul>
<h2 id="mechanism-of-action--pharmacokinetics-">Mechanism of Action &amp; Pharmacokinetics <sup id="fnref:1:1" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup></h2>
<ul>
  <li>Mimics acetylcholine by binding to nicotinic receptors at the neuromuscular junction, causing an initial depolarization (muscle fasciculations) followed by sustained depolarization, leading to paralysis.</li>
  <li>Onset of action is typically 30-60 seconds, with peak effect occurring within 1 minute.</li>
  <li>Duration of action is approximately 5-10 minutes due to rapid hydrolysis by plasma cholinesterase (pseudocholinesterase).</li>
</ul>
<h2 id="pharmacodynamics-">Pharmacodynamics <sup id="fnref:1:2" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup></h2>
<h3 id="cardiovascular">Cardiovascular</h3>
<ul>
  <li>Minimal direct cardiovascular effects, but may cause bradycardia, particularly in pediatric patients or with repeated dosing.
    <h3 id="respiratory">Respiratory</h3>
  </li>
  <li>Causes complete paralysis of respiratory muscles, requiring assisted ventilation until the drug wears off.
    <h3 id="neurological">Neurological</h3>
  </li>
  <li>Can cause increased intracranial pressure (ICP) transiently.</li>
</ul>
<h2 id="indications-">Indications <sup id="fnref:1:3" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup></h2>
<ul>
  <li>Rapid sequence induction and intubation.</li>
  <li>Situations requiring quick onset of muscle paralysis.</li>
</ul>
<h2 id="dosage-">Dosage <sup id="fnref:2" role="doc-noteref"><a href="#fn:2" class="footnote" rel="footnote">2</a></sup></h2>
<ul>
  <li><strong>Intubation Dose:</strong> 1-1.5 mg/kg IV based on total body weight (TBW).</li>
  <li><strong>Intramuscular Dose:</strong> 3-4 mg/kg IM based on total body weight (TBW).</li>
</ul>
<h2 id="contraindications-">Contraindications <sup id="fnref:1:4" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup></h2>
<ul>
  <li>History of malignant hyperthermia.</li>
  <li>Hyperkalemia or conditions that predispose to hyperkalemia (e.g., burns, severe trauma, spinal cord injuries).</li>
  <li>History of myopathies associated with elevated creatine kinase (CK) levels.</li>
</ul>
<h2 id="complications-">Complications <sup id="fnref:1:5" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup></h2>
<ul>
  <li>Bradycardia, especially with repeated doses in pediatric patients.</li>
  <li>Hyperkalemia</li>
  <li>Malignant hyperthermia in susceptible individuals.</li>
  <li>Fasciculations, which can cause postoperative myalgias.</li>
</ul>
<h2 id="references">References</h2>
<div class="footnotes" role="doc-endnotes">
  <ol>
    <li id="fn:1" role="doc-endnote">
      <p>Birdi T, Sullivan P. Ottawa Anesthesia Primer. Toronto, Ontario: Echo Book Publishing; 2012. <a href="#fnref:1" class="reversefootnote" role="doc-backlink">&#8617;</a> <a href="#fnref:1:1" class="reversefootnote" role="doc-backlink">&#8617;<sup>2</sup></a> <a href="#fnref:1:2" class="reversefootnote" role="doc-backlink">&#8617;<sup>3</sup></a> <a href="#fnref:1:3" class="reversefootnote" role="doc-backlink">&#8617;<sup>4</sup></a> <a href="#fnref:1:4" class="reversefootnote" role="doc-backlink">&#8617;<sup>5</sup></a> <a href="#fnref:1:5" class="reversefootnote" role="doc-backlink">&#8617;<sup>6</sup></a></p>
    </li>
    <li id="fn:2" role="doc-endnote">
      <p>De Baerdemaeker LE, Mortier EP, Struys MM. Pharmacokinetics in obese patients. Continuing Education in Anaesthesia Critical Care &amp; Pain. 2004 Oct;4(5):152–5. <a href="#fnref:2" class="reversefootnote" role="doc-backlink">&#8617;</a></p>
    </li>
  </ol>
</div>